Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Alto Neuroscience (ANRO) Receivables - Other (2023)

Alto Neuroscience has reported Receivables - Other over the past 1 years, most recently at $8000.0 for Q4 2023.

  • Quarterly results put Receivables - Other at $8000.0 for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $8000.0 (changed N/A YoY), and the annual figure for FY2023 was $8000.0, changed.
  • Receivables - Other reached $8000.0 in Q4 2023 per ANRO's latest filing.
  • Across five years, Receivables - Other topped out at $8000.0 in Q4 2023 and bottomed at $8000.0 in Q4 2023.